Group 1 - Novartis has been actively pursuing acquisition deals over the past year to strengthen its pipeline in response to patent expirations of key drugs like heart failure therapy, Kymriah [1][2] - On October 26, Novartis announced a proposed cash acquisition of Avidity Biosciences for approximately $12 billion to enhance its treatment portfolio for rare muscle diseases [1] - Avidity's latest market capitalization is close to $6.7 billion, and Novartis has completed nearly $20 billion in potential acquisition deals over the past year [1] Group 2 - Recent acquisitions by Novartis include: - $1.1 billion for gene therapy company Kate Therapeutics in November last year [2] - $3.1 billion for Anthos Therapeutics to enhance its cardiovascular treatment line in February [2] - $1.7 billion for Regulus Therapeutics for a kidney disease therapy in April [2] - Up to $1 billion agreement with Matchpoint Therapeutics for oral drugs targeting inflammatory diseases in July [2] - $1.4 billion acquisition of Tourmaline Bio for a cardiovascular treatment drug in September [2] - These acquisitions are aimed at addressing the patent expiration crisis of key drugs, with Novartis's stock price increasing approximately 34% this year, leading to a market capitalization exceeding $275 billion [2]